|
kEUR |
H1 2022 |
H1 2021 |
Change |
|
|
|
|
|
|
Revenue |
133,656 |
135,136 |
-1.1% |
|
Custom Projects |
72,613 |
76,207 |
-4.7% |
|
Contract Manufacturing |
48,398 |
45,765 |
5.8% |
|
Generics & Cosmetics |
12,645 |
13,164 |
-3.9% |
|
EBITDA |
26,706 |
39,889 |
-33.1% |
|
Adjusted 2 EBITDA |
26,706 |
43,240 |
-38.2% |
|
Adjusted 2 EBITDA in % of revenue |
20.0% |
32.0% |
-12.0 ppts |
|
Operating result (EBIT) |
15,482 |
30,803 |
-49.7% |
|
Operating result (EBIT) in % of revenue |
11.6% |
22.8% |
-11.2 ppts |
|
Result for the period |
10,247 |
24,623 |
-58.4% |
|
Result for the period in % of revenue |
7.7% |
18.2% |
-10.6 ppts |
|
Earnings per share (EUR), basic |
0.31 |
0.79 |
-60.9% |
|
Return on net operating assets (RONOA) |
14.3% |
25.6% |
-11.4 ppts |
|
Cash and cash equivalents (end of period) |
66,436 |
187,362 |
-64.5% |
|
Net cash flow from operating activities |
-7,659 |
41,048 |
-118.7% |
|
Capital expenditures |
37,926 |
24,989 |
51.8% |
|
Capital expenditures in % of revenue |
28.4% |
18.5% |
9.9 ppts |
|
Total assets (end of period) |
579,253 |
571,950 |
1.3% |
|
Equity ratio (end of period) |
73.8% |
67.4% |
6.3 ppts |
|
Employees (# of FTEs, average) |
1,156 |
1,026 |
12.7% |
1 This table and report include references to operational indicators and alternative financial performance measures (APM) that are not defined or specified by IFRS. These APM should be regarded as complementary information to and not as substitutes of the Group’s consolidated financial results based on IFRS. For the definitions of the main operational indicators and APM used, including related abbreviations, as well as for selected reconciliations to IFRS, please refer to the section “Definitions and reconciliations” of this report.
2 For H1 2022, no EBITDA adjustments were recognized. Adjusted EBITDA for H1 2021 excludes one-off IPO costs of EUR 5.7 million, partly offset by US government loans of EUR 2.4 million waived in context of the coronavirus pandemic.